Predictors of failure of first-line antiretroviral therapy in HIV-infected adults: Indian experience
- 1 July 2007
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 21 (Suppl 4), S47-S53
- https://doi.org/10.1097/01.aids.0000279706.24428.78
Abstract
To study the incidence and risk factors for failure of treatment with antiretroviral therapy among adults in the national treatment program in India, and to estimate the possible number of persons living with human immunodeficiency virus (HIV) who will need a second-line treatment regimen in the next 3 and 3.5 years. Data of a cohort of HIV-positive adult patients, who were enrolled in the government-sponsored antiretroviral therapy program, were obtained from the electronic medical record system of the largest HIV care center in India and subjected to analysis. Treatment failure defined by the World Health Organization criteria, assessed immunologically on the basis of CD4 T cell count, with a minimum period of 12 months of follow-up and with a minimum of two CD4 T cell follow-up measures. The cumulative incidence of treatment failure in the 1370 adult patients included in the study was 3.9% (95% confidence interval [CI] 2.9 to 4.9). Men had a 3.5 (1.6 to 7.4) times significantly greater risk of treatment failure. Patients who had negative changes in absolute lymphocyte count, hemoglobin concentration and body weight had 3.1 (1.6 to 6.2), 3.2 (1.6 to 6.2), and 3.5 (1.9 to 6.4) times significantly greater risk of treatment failure. In India, after 2007, by 2, 3, and 3.5 years, respectively, an estimated 16 000, 35 000, and 51 000 patients receiving antiretroviral therapy are likely to require second-line treatment. Monitoring of hemoglobin concentration, absolute lymphocyte count, and body weight during follow-up emerged as inexpensive predictors of treatment failure in a resource-poor setting. A significant number of patients will need second-line therapy as a result of failure of their first-line antiretroviral therapy regimen in 3 and 3.5 years in India, and therefore the development of an appropriate policy for second-line drugs is urgently needed.Keywords
This publication has 10 references indexed in Scilit:
- A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countriesThe Lancet Infectious Diseases, 2006
- Predictors of Immunological Failure after Initial Response to Highly Active Antiretroviral Therapy in HIV‐1–Infected Adults: A EuroSIDA StudyThe Journal of Infectious Diseases, 2004
- Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistanceThe Lancet, 2002
- Factors Related to Virologic Failure among HIV-Positive Injecting Drug Users Treated with Combination Antiretroviral Therapy Including Two Nucleoside Reverse Transcriptase Inhibitors and NevirapineAIDS Patient Care and STDs, 2002
- Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremiaAIDS, 2002
- Predictors of optimal virological response to potent antiretroviral therapyAIDS, 1999
- Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitorAIDS, 1998
- Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patientsAIDS, 1998
- Low Plasma Concentrations of Indinavir are Related to Virological Treatment Failure in HIV-1-Infected Patients on Indinavir-Containing Triple TherapyAntiviral Therapy, 1998
- Antiviral effect of double and triple drug combinations amongst HIV-infected adultsAIDS, 1998